Biomedical Research Foundation, Hospital Clínico San Calos-IdISSC, Madrid, Spain.
Department of Pharmacology, University of the Basque Country, UPV/EHU, Bizkaia, Spain.
Pediatr Res. 2024 Jun;95(7):1783-1790. doi: 10.1038/s41390-024-03077-8. Epub 2024 Feb 15.
Neonatal rats can manifest post-stroke mood disorders (PSMD) following middle cerebral artery occlusion (MCAO). We investigated whether cannabidiol (CBD) neuroprotection, previously demonstrated in neonatal rats after MCAO, includes prevention of PSMD development.
Seven-day-old Wistar rats (P7) underwent MCAO and received either vehicle or 5 mg/kg CBD treatment. Brain damage was quantified by MRI, and neurobehavioral and histological (TUNEL) studies were performed at P14 and P37. PSMD were assessed using the tail suspension test, forced swimming test, and open field tests. The dopaminergic system was evaluated by quantifying dopaminergic neurons (TH+) in the Ventral Tegmental Area (VTA), measuring brain dopamine (DA) concentration and DA transporter expression, and assessing the expression and function D2 receptors (D2R) through [35S]GTPγS binding. Animals without MCAO served as controls.
CBD reduced MCAO-induced brain damage and improved motor performance. At P14, MCAO induced depressive-like behavior, characterized by reduced TH+ cell population and DA levels, which CBD did not prevent. However, CBD ameliorated hyperactivity observed at P37, preventing increased DA concentration by restoring D2R function.
These findings confirm the development of PSMD following MCAO in neonatal rats and highlight CBD as a neuroprotective agent capable of long-term functional normalization of the dopaminergic system post-MCAO.
MCAO in neonatal rats led to post-stroke mood disorders consisting in a depression-like picture in the medium term evolving towards long-term hyperactivity, associated with an alteration of the dopaminergic system. The administration of CBD after MCAO did not prevent the development of depressive-like behavior, but reduced long-term hyperactivity, normalizing dopamine receptor function. These data point to the importance of considering the development of depression-like symptoms after neonatal stroke, a well-known complication after stroke in adults. Our work confirms the interest of CBD as a possible treatment for neonatal stroke.
新生大鼠在大脑中动脉闭塞(MCAO)后可表现出中风后情绪障碍(PSMD)。我们研究了大麻二酚(CBD)神经保护作用是否包括预防 PSMD 发展,此前在新生大鼠 MCAO 后已经证明了这种作用。
7 日龄 Wistar 大鼠(P7)接受 MCAO,并接受载体或 5mg/kg CBD 治疗。通过 MRI 量化脑损伤,在 P14 和 P37 进行神经行为和组织学(TUNEL)研究。通过悬尾试验、强迫游泳试验和旷场试验评估 PSMD。通过定量腹侧被盖区(VTA)中的多巴胺能神经元(TH+)、测量脑多巴胺(DA)浓度和 DA 转运体表达以及通过 [35S]GTPγS 结合评估 D2 受体(D2R)的表达和功能来评估多巴胺能系统。未进行 MCAO 的动物作为对照。
CBD 减少 MCAO 引起的脑损伤并改善运动表现。在 P14 时,MCAO 诱导出抑郁样行为,表现为 TH+细胞群和 DA 水平减少,CBD 不能预防这种情况。然而,CBD 改善了 P37 时观察到的多动,通过恢复 D2R 功能来防止 DA 浓度增加。
这些发现证实了新生大鼠 MCAO 后会出现 PSMD,并且强调了 CBD 作为一种神经保护剂,能够在 MCAO 后使多巴胺能系统的长期功能正常化。
新生大鼠 MCAO 导致中风后情绪障碍,包括中期出现的抑郁样表现,随着时间的推移发展为长期的多动,同时伴有多巴胺能系统的改变。MCAO 后给予 CBD 并不能预防抑郁样行为的发生,但可减少长期多动,使多巴胺受体功能正常化。这些数据表明,中风后抑郁样症状的发生是一个需要考虑的问题,这是成人中风的一个已知并发症。我们的工作证实了 CBD 作为新生儿中风治疗方法的潜在作用。